글로벌 항경련제 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

항경련제 시장 분석

글로벌 항경련제 시장은 간질 및 기타 신경계 질환의 유병률 증가에 힘입어 상당한 성장을 경험하고 있습니다. 약물 제형의 발전, 간질에 대한 인식 증가, 효과적인 치료 옵션에 대한 수요와 같은 요인이 시장 확장에 기여합니다. 게다가 발작 장애에 걸리기 쉬운 노인 인구가 증가하면서 시장의 잠재력이 더욱 증폭됩니다. 북미는 높은 의료비 지출과 활발한 연구 활동으로 인해 상당한 점유율을 차지하고 있습니다. 반면 아시아 태평양 지역은 의료 인프라 개선과 환자 수 증가로 인해 핵심 참여자로 부상하고 있습니다. 이 시장은 수많은 제약 회사가 혁신과 전략적 파트너십에 집중하여 제품 제공을 개선하는 경쟁적인 환경이 특징입니다.

항경련제 시장 규모

글로벌 항경련제 시장 규모는 2023년에 70억 8천만 달러로 평가되었으며, 2031년까지 103억 9천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 4.90%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

항경련제 시장 동향

“ 개인맞춤의학 발전 확대”

The anticonvulsants market is witnessing a notable trend toward the development of personalized medicine, which tailors treatment to individual patient profiles. This approach enhances the efficacy and minimizes side effects, addressing the unique responses patients have to different anticonvulsants. For instance, genetic testing can help determine which medications, such as lamotrigine or levetiracetam, are likely to be most effective for specific patients. This trend improves patient outcomes and drives market growth as healthcare providers increasingly adopt precision medicine practices. As a result, pharmaceutical companies are investing in research to develop targeted therapies, further revolutionizing the landscape of epilepsy treatment and shaping the future of the anticonvulsants market.

Report Scope and Anticonvulsants Market Segmentation     

Anticonvulsants Market Definition

Anticonvulsants are medications primarily used to prevent or reduce the frequency of seizures in individuals with epilepsy and other seizure disorders. They work by stabilizing electrical activity in the brain, thereby minimizing the occurrence of seizures. These drugs can also be prescribed for other conditions, such as bipolar disorder and neuropathic pain. Common instances include carbamazepine, phenytoin, and valproate. The effectiveness and side effects can vary significantly among patients, necessitating careful selection and monitoring by healthcare providers.

Anticonvulsants Market Dynamics

Drivers

• Increasing Prevalence of Epilepsy

The increasing prevalence of epilepsy significantly drives demand for anticonvulsant medications, with the World Health Organization estimating that around fifty million people worldwide are affected by this neurological disorder. In recent years, the incidence of epilepsy has been reported to be approximately 5-10 cases per 1,000 people, highlighting a growing need for effective treatment options. Moreover, advancements in diagnostic techniques and increased awareness of seizure disorders have led to better identification of affected individuals, allowing more patients to seek timely treatment. This rising awareness and subsequent demand for effective anticonvulsant medications create a significant market driver as healthcare providers strive to manage this chronic condition effectively.

• Increase in Neurological Disorders

The increase in neurological disorders significantly contributes to the growing demand for anticonvulsants, as conditions such Alzheimer’s disease and traumatic brain injuries often lead to seizures. According to the Alzheimer's Association, over 6 million Americans aged 65 and older are living with Alzheimer's disease, a number expected to rise as the population ages. Additionally, the Centers for Disease Control and Prevention (CDC) reports that traumatic brain injuries affect over 2 million people annually in the U.S., with a substantial proportion experiencing seizures as a consequence. These statistics illustrate the correlation between rising neurological disorders and the need for effective anticonvulsant therapies. As healthcare providers aim to manage the complexities associated with these conditions, the demand for anticonvulsants is expected to increase, positioning this factor as a critical market driver.

Opportunities

• Increasing Advancements in Drug Development

Advancements in drug development have significantly influenced the anticonvulsant market by introducing newer medications with enhanced efficacy and safety profiles, presenting substantial market opportunities. For instance, medications such as Lacosamide and Perampanel have emerged in recent years, providing alternatives for patients who do not respond well to traditional treatments. Lacosamide, approved in the U.S. in 2008, has shown effectiveness in treating partial-onset seizures and has a favorable safety profile, making it a preferred choice for many patients. Furthermore, innovations in drug formulation and delivery methods, such as extended-release formulations and personalized medicine approaches, allow for better patient adherence and optimized therapeutic outcomes. These continuous developments highlight the potential for growth in the anticonvulsant market as pharmaceutical companies invest in research and innovation to meet the evolving needs of patients.

• Growing Awareness and Improved Diagnosis

Growing awareness and improved diagnosis of neurological disorders have significantly expanded the patient population in need of anticonvulsant therapies, creating a valuable market opportunity. Initiatives such as public awareness campaigns and educational programs for healthcare providers have led to increased recognition of symptoms associated with epilepsy and other seizure disorders. For instance, the Epilepsy Foundation's "Seize the Awareness" campaign aims to educate both the public and medical professionals about seizure recognition and response, contributing to more timely diagnoses. This heightened awareness facilitates early intervention and drives demand for effective anticonvulsant treatments, providing pharmaceutical companies with the opportunity to cater to a growing market of newly diagnosed patients.

Restraints/Challenges

• Adverse Effects and Side Effects

Adverse effects and side effects associated with anticonvulsant medications pose significant challenges to patient compliance, often leading to non-adherence to treatment regimens. Common side effects include dizziness, fatigue, and cognitive impairment, which can deter patients from continuing their prescribed therapies. For instance, medications such as Carbamazepine and Lamotrigine are effective in managing seizures but can cause drowsiness and cognitive dulling, leading patients to skip doses or abandon treatment altogether. Furthermore, long-term safety concerns related to these medications, such as potential organ damage or increased risk of suicidal thoughts, can create apprehension among both patients and healthcare providers. This hesitance to utilize certain anticonvulsants due to fear of long-term consequences affects individual patient outcomes and presents a broader market challenge, as it limits the adoption of potentially effective therapies in clinical practice.

• High Treatment Costs Associated Novel Therapies

High treatment costs associated with certain anticonvulsants, particularly novel therapies, present a significant barrier to access for patients, especially in low- and middle-income countries. For instance, newer medications such as Brivaracetam and Lacosamide can be significantly more expensive than traditional anticonvulsants, making them unaffordable for many patients who rely on these treatments for seizure management. Additionally, inconsistent reimbursement policies across various regions exacerbate this issue, as some countries may not cover the costs of these newer medications under their national health insurance programs, limiting access for those who need them most. In regions where reimbursement is lacking or varies widely, patients may be forced to choose less effective, older therapies due to financial constraints, which impacts individual health outcomes and stifles overall market growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Anticonvulsants Market Scope

The market is segmented on the basis of drug class, dosage, route of administration, application, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

• Pyrimidinediones
• Benzodiazepines
• Fructose derivatives
• Aromatic allylic alcohols
• Valproylamides
• Carboxamides
• Bromides
• Carbamates
• Aldehydes
• Sulfonamides
• Pyrrolidines
• Triazines
• Fatty acids
• Propionates
• Oxazolidinediones
• Hydantoins
• Barbiturates
• Others

Dosage

• Tablet
• Capsule
• Liquid
• Rectal Gel
• Cream
• Others

Route of Administration

• Topical
• Enteral
• Parenteral

Application

• Migraine
• Epilepsy
• Neuropathic pain
• Anxiety
• Fibromyalgia
• Bipolar Disorder
• Borderline Personality Disorder

End Users

• Clinic
• Hospital
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Anticonvulsants Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, drug class, dosage, route of administration, application, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is anticipated to lead the global Anticonvulsants market, primarily driven by significant investments in the healthcare sector that are projected to stimulate market expansion. Within this region, the United States is expected to take the lead, largely due to its rapid technological advancements in healthcare solutions and innovative treatment options. Additionally, the growing emphasis on early disease detection and personalized medicine in the U.S. further enhances the demand for Anticonvulsants, contributing to the region's dominance in this market.

아시아 태평양 지역은 2024년부터 2031년까지 상당한 성장을 경험할 것으로 예상되며, 이는 주로 제네릭 및 브랜드 형태의 아지트로마이신이 환자에게 더 쉽게 접근 가능해짐에 따라 촉진됩니다. 생물제약 분야의 급속한 발전은 혁신적인 치료법 개발에 기여하여 시장 확장을 더욱 촉진합니다. 이 지역의 연구 개발 활동이 증가함에 따라 약물 발견 및 개선을 위한 역동적인 환경이 조성되고 있습니다. 또한, 의료 분야의 지속적인 발전과 강력한 정부 지원 및 의료 접근성과 경제성을 개선하기 위한 이니셔티브는 아시아 태평양 지역의 항경련제 시장의 전반적인 성장을 뒷받침할 것으로 예상됩니다.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.  

항경련제 시장 점유율

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 운영되는 항경련제 시장 리더는 다음과 같습니다.

• 노바티스 AG(스위스)
• 사노피(프랑스)
• 파이저 주식회사(미국)
• 존슨앤존슨 프라이빗 리미티드(미국)
• 애벗(미국)
• Teva Pharmaceutical Industries Ltd. (이스라엘)
• Bausch Health Companies Inc. (미국)
• UCB SA(벨기에)
• Sunovion Pharmaceuticals Inc. (미국)
• GW Pharmaceuticals plc (영국)
• 아스트라제네카(영국)
• GSK plc (영국)
• H. Lundbeck A/S(덴마크)
• 다케다제약 주식회사(일본)
• 스미토모 다이닛폰 제약 주식회사(일본)
• Biocon(인도)
• 머크 KGaA(독일)
• 카딜라(인도)
• 에자이 주식회사(일본)
• 시플라(인도)
• Glenmark Pharmaceuticals Limited(인도)
• Mankind Pharma(인도)
• Novo Nordisk A/S(덴마크)
• 오츠카 아메리카 제약 주식회사(일본)
• 워크하르트(인도)

항경련제 시장의 최신 동향

• 2022년 12월, Eisai Co., Ltd.는 항경련제(AED) Fycompa에 대한 미국 상업적 권리를 Catalyst Pharmaceuticals, Inc.에 양도하는 계약을 발표했으며, 이를 통해 Catalyst는 Eisai의 간질 파이프라인 내 잠재적 자산에 대한 독점적 협상 기간을 확보하게 됩니다.
• 2022년 8월, UCB SA는 Bonheur Children's Hospital, Wisconsin Health Information Organization(WHIO), Yale University와 포괄적인 3개 계약을 체결했습니다. 이러한 파트너십은 발작 클러스터 환자가 직면한 과제를 더 깊이 파고들어 이 질환에 대한 인식을 높이는 것을 목표로 합니다.
• 2022년 2월, Biohaven Pharmaceutical Holding Company Ltd.는 간질, 통증 장애, 정서 장애를 포함한 적응증을 타겟으로 Channel Biosciences, LLC로부터 Kv7 채널 활성제를 인수하기 위한 계약을 마무리했습니다.
• 2021년 8월, UCB SA는 미국 식품의약국(FDA)으로부터 BRIVIACT(브리바라세탐)에 대한 정제, 주사제 및 경구용액 형태의 확대 적응증에 대한 승인을 받았으며, 이로써 부분 발작이 있는 1개월 된 어린 환자도 치료할 수 있게 되었습니다.
• 2021년 8월, Pfizer Inc.와 Flynn Pharma는 일반적으로 사용되는 간질 치료제에 대해 국민건강보험공단(NHS)에 과도한 요금을 청구한 혐의로 영국 경쟁 및 시장청(CMA)으로부터 8,400만 달러의 벌금을 부과받았습니다.

SKU-66107